The FDA approved Biogen's Alzheimer's drug. That's great news for Biogen and its shareholders, but it's also fantastic news for a competitor. Read More

The third-quarter earnings season has gotten off to a better-than-expected start, but here’s why the numbers can be deceptive. Read More